Celltrion’s Yuflyma receives US FDA approval for multiple conditions
Pharmaceutical Technology
MAY 25, 2023
It is already the first proposed high-concentration (100mg/mL), low-volume and citrate-free adalimumab biosimilar in the world to receive marketing authorisation from the European Commission. Yuflyma represents the company’s fifth biosimilar and second anti-TNF biosimilar to receive US FDA approval.
Let's personalize your content